加强甲状腺结节及恶性肿瘤的规范治疗

doi:10.6040/j.issn.1673-3770.1.2020.037

摘要/Abstract

摘要： 近年来,甲状腺结节和甲状腺癌的发病率逐渐增高。针对甲状腺结节和甲状腺癌的诊断和治疗技术快速发展,分子生物学检测手段成为甲状腺恶性肿瘤诊断的重要补充,为临床决策提供了更多有价值的信息。新的治疗方式不断出现,比如颈外径路腔镜辅助甲状腺手术以及机器人手术,很大程度上满足了患者对于美观的诉求。与此同时,越来越多的争议和讨论相应出现,如射频消融技术在甲状腺结节中的应用价值、分化型甲状腺癌的切除范围、预防性中央区淋巴结清扫的指征、侧颈淋巴结清扫的范围、放射性碘治疗的指征等。将理论研究与临床实践相结合,讨论并概述了甲状腺结节与甲状腺癌的疾病特点、诊断、治疗、随访等环节的争议热点和最新进展,为该类疾病的临床管理提供方法和思路。

关键词: 甲状腺结节, 分化型甲状腺癌, 甲状腺未分化癌, 射频消融, 机器人手术, 颈外径路, 放射性碘治疗

中图分类号:

R739.91

潘新良. 加强甲状腺结节及恶性肿瘤的规范治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 1-12.

PAN Xinliang. Improving the standard treatments for thyroid nodules and malignant tumors[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 1-12.

参考文献

[1] 张晋熙, 姜玉新. 浅表器官及组织超声诊断学[M]. 北京:科学技术文献出版社, 2009:22.
[2] 苏应瑞, 查金顺, 李拾林, 等. 甲状腺锥状叶影像解剖特点及临床意义[J]. 中国临床解剖学杂志, 2012, 30(6): 651-654. doi:10.13418/j.issn.1001-165x.2012.06.022. SU Yingrui, ZHA Jinshun, LI Shilin, et al. Imaging anatomy and clinical significance of the pyramidal lobe of thyroid gland[J]. Chinese Journal of Clinical Anatomy, 2012, 30(6): 651-654. doi:10.13418/j.issn.1001-165x.2012.06.022.
[3] 刘家锋. Zuckerkandl结节在甲状腺外科中的重要意义[J]. 中国临床解剖学杂志, 2019, 37(1): 107-109. doi:10.13418/j.issn.1001-165x.2019.01.022. LIU Jiafeng. The significance of Zuckerkandl'stubercel in thyroid surgery[J]. Chinese Journal of Clinical Anatomy, 2019, 37(1): 107-109. doi:10.13418/j.issn.1001-165x.2019.01.022.
[4] 张勤修, 叶静, 李满. 甲状腺手术中精细化被膜解剖法的应用[J]. 临床耳鼻咽喉科杂志, 2005, 19(12): 552-553. ZHANG Qinxiu, YE Jing, LI Man. Application of metlculous capsular dissection technique in thyroidectomy[J]. Journal of Clinical Otorhinolaryngology, 2005, 19(12): 552-553.
[5] 孙辉. 甲状腺的应用解剖与生理[J].中国社区医师,1991(7):9-10.
[6] Shan ZY, Chen LL, Lian XL, et al. Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China: a cross-sectional study in 10 cities[J]. Thyroid, 2016, 26(8): 1125-1130. doi:10.1089/thy.2015.0613.
[7] Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors[J]. J Cancer Epidemiol, 2013, 2013: 965212. doi:10.1155/2013/965212.
[8] Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA: A Cancer J Clin, 2010, 60(5): 277-300. doi:10.3322/caac.20073.
[9] Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002[J]. JAMA, 2006, 295(18): 2164-2167. doi:10.1001/jama.295.18.2164.
[10] Morris LG, Sikora AG, Tosteson TD, et al. The increasing incidence of thyroid cancer: the influence of access to care[J]. Thyroid, 2013, 23(7): 885-891. doi:10.1089/thy.2013.0045
[11] Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, et al. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States[J]. Ann Surg Oncol, 2013, 20(8): 2746-2753. doi:10.1245/s10434-013-2892-y.
[12] Enewold L, Zhu KM, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(3): 784-791. doi:10.1158/1055-9965.EPI-08-0960.
[13] Kent WD, Hall SF, Isotalo PA, et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease[J]. J De L'association Med Can, 2007, 177(11): 1357-1361. doi:10.1503/cmaj.061730.
[14] Kent WD, Hall SF, Isotalo PA, et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease[J]. J De L'association Med Can, 2007, 177(11): 1357-1361. doi:10.1503/cmaj.061730.
[15] Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J]. JAMA, 2017, 317(13): 1338-1348. doi:10.1001/jama. 2017.2719.
[16] Ibrahimpasic T, Ghossein R, Shah JP. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects[J].Thyroid: official journal of the American Thyroid Association, 2019,29(3):311-321. DOI:10.1089/thy.2018.0509.
[17] Krátký J, Vítková H, Bartáková J, et al. Thyroid nodules: pathophysiological insight on oncogenesis and novel diagnostic techniques[J]. Physiol Res, 2014,63(2):263-275.
[18] Huan Q, Wang K, Lou FC, et al. Epidemiological characteristics of thyroid nodules and risk factors for malignant nodules: a retrospective study from 6, 304 surgical cases[J]. Chin Med J, 2014, 127(12): 2286-2292.
[19] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid: official journal of the American Thyroid Association,2016,26(1):1-133. DOI:10.1089/thy.2015.0020
[20] 宋韫韬, 张彬. 术前细针穿刺细胞学的分子检测在甲状腺癌诊断和治疗中的研究进展[J]. 中华耳鼻咽喉头颈外科杂志,2019,54(1):58-61. doi:10.3760/cma.j.issn.1673-0860. 2019.01.015. SONG Yuntao, ZHANG Bin. Preoperative molecular testing on fine-needle aspiration in precision management of thyroid cancer[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2019,54(1):58-61. doi:10.3760/cma.j.issn.1673-0860.2019.01.015.
[21] Guth S, Theune U, Aberle J, et al. Very high prevalence of thyroid nodules detected by high frequency(13 MHz)ultrasound examination[J]. Eur J Clin Invest, 2009, 39(8): 699-706. doi:10.1111/j.1365-2362.2009.02162.x.
[22] Na DG, Lee JH, Jung SL, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations[J]. Korean J Radiol, 2012,13(2):117-25. doi: 10.3348/kjr.2012.13.2.117.
[23] Sim JS, Baek JH, Lee J, et al. Radiofrequency ablation of benign thyroid nodules: depicting early sign of regrowth by calculating vital volume[J]. Int J Hyperthermia, 2017, 33(8): 905-910. doi:10.1080/02656736.2017.1309083.
[24] Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer[J]. Ann Surg Oncol, 2005, 12(1): 81-89. doi:10.1007/s10434-004-1165-1.
[25] Nixon IJ, Wang LY, Palmer FL, et al. The impact of nodal status on outcome in older patients with papillary thyroid cancer[J]. Surgery, 2014, 156(1): 137-146. doi:10.1016/j.surg.2014.03.027.
[26] Won HR, Chang JW, Kang YE, et al. Optimal extent of lateral neck dissection for well-differentiated thyroid carcinoma with metastatic lateral neck lymph nodes: A systematic review and meta-analysis[J]. Oral Oncol, 2018,87:117-125. doi: 10.1016/j.oraloncology.2018.10.035.
[27] Turanli S. Is the type of dissection in lateral neck metastasis for differentiated thyroid carcinoma important[J]. Otolaryngol Head NeckSurg, 2007, 136(6):957-960. doi:10.1016/j.otohns.2006.12.013.
[28] Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J].Ann SurgOncol, 2010, 17(6): 1471-1474. doi: 10.1245/s10434-010-0985-4.
[29] Shin DH, Mark EJ, SuenHC, et al. Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea: a clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resection[J]. Hum Pathol, 1993, 24(8): 866-870.
[30] Evaluation and treatment of aerodigestive tract invasion by well-differentiated thyroid carcinoma[J]. Cancer control: journal of the Moffitt Cancer Center, 2000,7(3):246-252.
[31] 李丽娅, 易红良. 侵犯喉气管的甲状腺癌治疗研究进展[J]. 中华耳鼻咽喉头颈外科杂志, 2016,51(9):716-720. doi: 10.3760/cma.j.issn.1673-0860.2016.09.020. LI Liya, YI Hongliang. Advances of the treatments for thyroid carcinoma patients with laryngotracheal invasion[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2016,51(9):716-720. doi:10.3760/cma.j.issn.1673-0860.2016.09.020.
[32] Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma[J].Med ClinNoth Am,2017, 96(2):369-383. doi: 10.1016/j.mcna.2012.01.002.
[33] 张亮, 刘业海, 吴开乐, 等. 侵犯喉气管或/和下咽颈段食管的甲状腺癌的外科治疗[J]. 中国中西医结合耳鼻咽喉科杂志, 2016, 24(5): 377-379, 400. doi:10.16542/j.cnki.issn.1007-4856.2016.05.016.
[34] Ohgami M, Ishii S, Arisawa Y, et al. Scarless endoscopic thyroidectomy: breast approach for better cosmesis[J]. Surg Laparosc Endosc Percutan Tech, 2000, 10(1): 1-4.
[35] Jung EJ, Park ST, Ha WS, et al. Endoscopic thyroidectomy using a gasless axillary approach[J]. J LaparoendoscAdvSurg Tech, 2007, 17(1): 21-25. doi:10.1089/lap.2006.05112.
[36] Shimazu K, Shiba E, Tamaki Y, et al. Endoscopic thyroid surgery through the axillo-bilateral-breast approach[J]. Surg Laparosc Endosc Percutan Tech, 2003, 13(3): 196-201. doi:10.1097/00129689-200306000-00011.
[37] Choe JH, Kim SW, Chung KW, et al. Endoscopic thyroidectomy using a new bilateral axillo-breast approach[J]. World J Surg, 2007, 31(3): 601-606. doi:10.1007/s00268-006-0481-y.
[38] Lee KE, Kim HY, Park WS, et al. Postauricular and axillary approach endoscopic neck surgery: a new technique[J]. World J Surg, 2009, 33(4): 767-772. doi:10.1007/s00268-009-9922-8.
[39] Witzel K, von Rahden BHA, Kaminski C, et al. Transoral access for endoscopic thyroid resection[J]. Surg Endosc, 2008, 22(8): 1871-1875. doi:10.1007/s00464-007-9734-6.
[40] Kang SW, Jeong JJ, Yun JS, et al. Robot-assisted endoscopic surgery for thyroid cancer: experience with the first 100 patients[J]. Surg Endosc, 2009, 23(11): 2399-2406. doi:10.1007/s00464-009-0366-x.
[41] Sasaki A, Nakajima J, Ikeda K, et al. Endoscopic thyroidectomy by the breast approach: a single institution's 9-year experience[J]. World J Surg, 2008,32(3):381-385. doi:10.1007/s00268-007-9375-x.
[42] Duncan TD, Rashid Q, Speights F, et al. Endoscopic transaxillary approach to the thyroid gland: our early experience[J]. Surg Endosc, 2007, 21(12): 2166-2171. doi:10.1007/s00464-007-9325-6.
[43] Choe JH, Kim SW, Chung KW, et al. Endoscopic thyroidectomy using a new bilateral axillo-breast approach[J]. World J Surg, 2007, 31(3): 601-606. doi:10.1007/s00268-006-0481-y.
[44] Puntambekar S, Sharma V, Kumar S, et al. Management of large size MNGs and STNs using 3D endoscopic technique: a review of 10 cases[J]. Indian J Surg, 2016, 78(2): 117-120. doi:10.1007/s12262-015-1330-8.
[45] Nakajo A, Arima H, Hirata M, et al. Trans-Oral Video-Assisted Neck Surgery(TOVANS). A new transoral technique of endoscopic thyroidectomy with gasless premandible approach[J]. Surg Endosc, 2013, 27(4): 1105-1110. doi:10.1007/s00464-012-2588-6.
[46] Terris DJ, Chin E. Clinical implementation of endoscopic thyroidectomy in selected patients[J]. Laryngoscope, 2006, 116(10): 1745-1748. doi:10.1097/01.mLg.0000233243.28872.26.
[47] Lorenz K, Abuazab M, Sekulla C, et al. Results of intraoperative neuromonitoring in thyroid surgery and preoperative vocal cord paralysis[J]. World J Surg, 2014, 38(3): 582-591. doi:10.1007/s00268-013-2402-1.
[48] Tan Z, Gu JL, Han QB, et al. Comparison of conventional open thyroidectomy and endoscopic thyroidectomy via breast approach for papillary thyroid carcinoma[J]. Int J Endocrinol, 2015, 2015: 239610. doi:10.1155/2015/239610.
[49] Cabot JC, Lee CR, Brunaud L, et al. Robotic and endoscopic transaxillary thyroidectomies may be cost prohibitive when compared to standard cervical thyroidectomy: a cost analysis[J]. Surgery, 2012, 152(6): 1016-1024. doi:10.1016/j.surg.2012.08.029.
[50] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等. 甲状腺结节和分化型甲状腺癌诊治指南[J].中华内分泌代谢杂志, 2012,28(10): 779-797. doi: 10.3760/cma.j.issn.1000-6699.2012.10.002.
[51] 王荣福. 碘131对分化型甲状腺癌的治疗应用进展[J]. 肿瘤学杂志, 2012, 18(10): 742-745. doi: 10.11735/j.issn.1671-170X.2012.10.B007. WAHG Rongfu. Progress in iodine 131 for the treatment of differentiated thyroid cancer[J]. Journal of Oncology, 2012, 18(10): 742-745. doi: 10.11735/j.issn.1671-170X.2012.10.B007.
[52] van Tol KM, Jager PL, de Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin[J]. Eur J Endocrinol, 2003,148(6):589-596.
[53] Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer[J].N Engl J Med, 2016, 375(11):1054-1067. doi: 10.1056/NEJMra1501993.
[54] 潘宗富, 方琦璐, 张轶雯, 等. 甲状腺未分化癌治疗研究进展: 免疫疗法与分子靶向治疗[J]. 中国药师, 2019, 22(3): 518-522.doi:CNKI:SUN:ZYSG.0.2019-03-036. PAN Zongfu, FANG Qilu, ZHANG Yiwen, et al. Progress in the treatment of anaplastic thyroid carcinoma: immunotherapy and molecular targeted therapy[J]. China Pharmacist, 2019, 22(3):518-522. doi:CNKI:SUN:ZYSG.0.2019-03-036.
[55] 孙传政, 陈福进, 曾宗渊, 等. 甲状腺未分化癌的治疗和预后[J]. 中华外科杂志, 2006, 44(21): 1493-1497. doi:10.3760/j:issn:0529-5815.2006.21.017. SUN Chuanzheng, CHEN Fujin, ZENG Zongyuan, et al. Treatment and prognosis of anaplastic thyroid carcinoma[J]. Chinese Journal of Surgery, 2006, 44(21): 1493-1497.doi:10.3760/j:issn:0529-5815.2006.21.017.
[56] 冯影, 高明. 94例甲状腺未分化癌临床分析[J]. 天津医科大学学报, 2008, 14(2): 207-209. doi:10.3969/j.issn.1006-8147.2008.02.023. FENG Ying, GAO Ming. Clinical and pathological analysis of patients with anaplastic thyroid carcinoma[J]. Journal of Tianjin Medical University, 2008, 14(2): 207-209. doi:10.3969/j.issn.1006-8147.2008.02.023.
[57] Carling T, Udelsman R. Thyroid cancer[J]. Annu Rev Med, 2014, 65(1): 125-137. doi:10.1146/annurev-med-061512-105739.
[58] Haddad RI, Lydiatt WM, Ball DW, et al. Anaplastic Thyroid Carcinoma, Version 2.2015[J].J Natl Compr Canc Netw, 2015,13(9):1140-1150.
[59] Wells SA, Asa SL, Dralle H, etal. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid: official journal of the American Thyroid Association, 2015,25(6):567-610. doi:10.1089/thy.2014.0335.
[60] Wu LS, Roman SA, Sosa JA. Medullary thyroid cancer: an update of new guidelines and recent developments[J]. Curr Opin Oncol. 2011, 23(1):22-7. doi: 10.1097/CCO.0b013e328340b527.
[61] Emerson CH. Thyroid: the official journal of the American thyroid association[J]. Thyroid, 2008, 18(9): 929-930. doi:10.1089/thy.2008.1548.
[62] Bussières V, Roy S, DeladoeyJ,et al. Prophylactic thyroidectomies in MEN2 syndrome: Management and outcomes[J]. J PediatrSurg, 2018,53(2):283-285. doi: 10.1016/j.jpedsurg.2017.11.015.
[63] 中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版)[J]. 中华普通外科学文献(电子版), 2019, 13(1): 1-15. doi: 10.3877/cma.j.issn.1674-0793.2019.01.001.
[64] Lamartina L, Grani G, Durante C,et al. Follow-up of differentiated thyroid cancer-what should(and what should not)be done[J]. Nat Rev Endocrinol, 2018,14(9):538-551. doi: 10.1038/s41574-018-0068-3.
[65] Grani G, Ramundo V, VerrientiA,et al. Thyroid hormone therapy in differentiated thyroid cancer[J].Endocrine,2019,66(1):43-50.doi:10.1007/s12020-019-02051-3.
[66] Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5): 418-428. doi:10.1016/0002-9343(94)90321-2.
[67] Shoup M, Stojadinovic A, Nissan A, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma[J]. J Am Coll Surg, 2003, 197(2): 191-197. doi:10.1016/S1072-7515(03)00332-6.
[68] Lamartina L, Cooper DS. Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the “con” point of view[J]. Endocrine, 2015, 50(1): 67-71. doi:10.1007/s12020-014-0523-4.
[69] Leenhardt L, Erdogan MF, Hegedus L, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer[J]. Eur Thyroid J, 2013, 2(3): 147-159. doi:10.1159/000354537.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed